Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm decreased their price target on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, September 23rd.

Aptevo Therapeutics Price Performance

Shares of NASDAQ:APVO opened at $0.14 on Monday. The business’s 50 day simple moving average is $0.29 and its 200 day simple moving average is $0.68. Aptevo Therapeutics has a 1 year low of $0.14 and a 1 year high of $16.57.

Aptevo Therapeutics (NASDAQ:APVO) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.26. On average, equities analysts predict that Aptevo Therapeutics will post -2.97 EPS for the current year.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is currently owned by institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.